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Abstract
Background: Little information is available about infantile visceral leishmaniasis (VL) in Albania as regards incidence,
diagnosis and management of the disease.
Methodology/Principal Findings: Demographic data, clinical and laboratory features and therapeutic findings were
considered in children admitted to University Hospital of Tirana from 1995 to 2009, and diagnosed as having VL. The
diagnosis was based on bone-marrow microscopy/culture in 77.5% of patients, serology in 16.1%, and ex juvantibus in 6.4%.
A total of 1,210 children were considered, of whom 74% came from urbanized areas. All patients were in the age range 0–14
years, with a median of 4 years. Hepatosplenomegaly was recorded in 100%, fever in 95.4% and moderate to severe anemia
in 88% of cases. Concomitant conditions were frequent: 84% had bronchopneumonia; diarrhea was present in 27%, with
acute manifestations in 5%; 3% had salmonellosis. First-line therapy was meglumine antimoniate for all patients, given at
the standard Sb
v dosage of 20 mg/kg/day for 21 to 28 days. Two children died under treatment, one of sepsis, the other of
acute renal impairment. There were no cases of primary unresponsiveness to treatment, and only 8 (0.67%) relapsed within
6–12 months after therapy. These patients have been re-treated with liposomal amphotericin B, with successful cure.
Conclusions: Visceral leishmaniasis in pediatric age is relatively frequent in Albania; therefore an improvement is warranted
of a disease-specific surveillance system in this country, especially as regards diagnosis. Despite recent reports on decreased
responses to antimonial drugs of patients with Mediterranean VL, meglumine antimoniate treatment appears to be still
highly effective in Albania.
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Introduction
Zoonotic visceral leishmaniasis (VL) is a disseminated protozoan
infection transmitted by phlebotomine sandflies, caused by
Leishmania infantum in areas of the Old and New Worlds [1]. In
Mediterranean countries, about 1,000 people are estimated to be
affected by clinical disease annually [2] although asymptomatic or
sub-clinical cases are by far more frequent [3–5]. Mediterranean
VL affects primarily children as well as an increasing rate of
immunocompromised and immunosuppressed adult individuals,
such as HIV- infected [6] and patients under any immunosuppres-
sive therapies [7–8]. The disease is known to occur in Albania since
1938 typically as a childhood disease [9]; however, despite being a
notifiable disease in the country, VL case records and statistics have
not been available to international health organizations (such as
World Health Organization) nor to the scientific community for
long time. Albania is a developing country that is progressively
increasing its social, economic and sanitary relationships with
western countries. However, being its health care system still in
progress, there are incomplete data on the clinical epidemiology of
some infectious diseases. In particular, little information is available
about VL in children as regards disease diagnosis and management.
Herein we present the data derived from an observational
retrospective cohort study performed at the University Hospital
‘‘Mother Theresa’’ of Tirana (UHT), aimed at the analysis of the
epidemiological, clinical, diagnostic and therapeutic features of
pediatric VL in Albania in the 1995–2009 period.
Methods
Study design, diagnosis and treatment
We evaluated the data regarding 1,210 children admitted from
1995 to 2009 to the Infectious Diseases ward of UHT, the largest
pediatric hospital of Albania (about 400 beds). The ward (45 beds)
is the national reference centre where any Albanian children
suspected or diagnosed for VL in peripheral hospitals are referred
for diagnosis and/or treatment. Demographic, clinical and
laboratory findings were collected prospectively into a database
and the data analyzed retrospectively by the UHT medical staff
(RP and LK).
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the guidelines for VL management approved by the Ministry of
Health and adopted by the sanitary directorship of UHT. They
include the following general examinations: full hematologic
assessment, biochemical profile (serum urea, creatinine, ALT,
total proteins, protein electrophoresis and bilirubin), electro-
lytes (K+), hemoculture, urine examination, ECG, chest x-ray
and abdominal sonography. Among infectious diseases, differ-
ential diagnosis includes brucellosis, abdominal typhus and
HIV.
First-line VL diagnosis was based on the microscopic
demonstration of Leishmania amastigotes on Giemsa-stained
smears of bone marrow aspirates. Aspirate material was also
seeded in culture media for Leishmania ( N N N ,E v a n s ’M o d i f i e d
Tobie’s or MEM media) when available from the Tirana
Institute of Public Health. If direct parasitological diagnosis
proved negative but strong clinical suspicion of VL persisted,
search for anti-Leishmania antibodies was performed using ELISA
or IFAT commercial kits (IgG and IgM, BioMerieux, France).
This second-line serological approach has been in use starting
from 1999. When serology could not be performed because of
shortage of kits due to financial constraints, patient’s parents or
guardians were recommended to send sera to private laborato-
ries by their own. In case border-line serology results, a new
serum sample was examined after one week by two different
laboratories. In patients with negative bone marrow and
negative or border-line serology, but showing persisting clinical
and laboratory features suggestive of VL without evidence of
other systemic diseases, presumptive treatment was administered
and diagnosis performed ex juvantibus. Upon diagnosis, the first-
line treatment was administered in hospital using meglumine
antimoniate once daily, given intramuscularly, at the Sb
v dosage
of 20 mg/kg/day for 21 to 28 days. Patients relapsing following
initial cure were re-treated using intravenous liposomal ampho-
tericin B at the dose of 3 mg/kg/day in days 1–5, 14 and 21
[10]. Treatment-associated adverse events of grade 2 or higher
were considered.
Ethical considerations
Clinical samples were collected from children suspected as
having VL, following the national guidelines for laboratory
diagnosis of the disease at UHT. Informed written consent was
obtained from parents or guardians and recorded on the medical
chart before performing bone-marrow aspiration. The study was
approved by the National Committee of Bioethics, Ministry of
Health, Republic of Albania.
Results
Demography and epidemiology
The yearly number of admitted patients ranged from 63 to 146,
with a mean of admitted per-year of 93 patients. The monthly
distribution of cases referred to the date of hospitalization and VL
diagnosis is shown in the graph of Figure 1. Cases were identified
in all months, with a minimum in September (61 cumulative cases)
and a maximum in July (174 cases). The main cluster was in the
May–July period (487 cases, 40%). Because over half of the
patients referred onset of symptoms 1–3 months before hospital
admittance (see below), the cluster is consistent with the usual long
incubation period (around 6 months) of L. infantum infections
transmitted late in the preceding sand fly season (May–October)
[9].
Seventy-four % of patients came from urbanized areas, mainly
from peripheral districts of Shkode ¨r and Lezhe ¨ in the north,
Tirana in the centre and Lushnje ¨, Fier, Berat and Vlore ¨ in the
south, whereas 26% were from rural areas represented by coastal
or lake territories. All districts of Albania were involved, with
large variations in the distribution of cases. A map showing the
stratification of cumulative cases by district is shown in Figure 2.
The age of patients ranged from 0 to 14 years (median: 4 years).
The majority of cases belonged to the 1–4 years age group (61%).
Sixteen % were in 0–1, 17% in 4–10 and 6% in 10–14 years age
groups, respectively. Fifty-eight% were males.
Clinical features and laboratory data
At the admittance, 42.2% of patients reported the onset of
symptoms in the last 30 days or less, for a minimum of 10 days,
and 57.8% since more than 30 days, for a maximum of 3 months.
At presentation only 4.5% of the patients was afebrile; fever
.38uC was recorded in 63.3% of patients. In Table 1 the main
VL symptoms and signs of the patients and data from physical
examination are summarized. Regarding hematological evalua-
tion, the most frequent finding was anemia (99.8%) with a mean
value of hemoglobin 7.0 g/dl. Hematological and biochemical
features recorded at admittance are shown in Table 2. In addition,
concomitant conditions were frequently recorded: 84% of patients
Figure 1. Seasonal distribution by month of diagnosis of 1210
pediatric cases of visceral leishmaniasis diagnosed from 1995
through 2009.
doi:10.1371/journal.pntd.0000814.g001
Author Summary
Albania is a developing country that is rapidly improving in
social, economic and sanitary conditions. The health care
system in still in progress and the impact of some
infectious diseases remains poorly understood. In partic-
ular, little information is available on incidence, clinical
features and response to treatment of visceral leishman-
iasis (VL) in childhood. We performed a retrospective
analysis of data recorded from 1995 to 2009 at the national
pediatric reference hospital of Tirana where any child
suspected for VL is referred for specific diagnosis and
treatment. Epidemiology, clinical features and manage-
ment of the disease were considered. The main findings
can be summarized as follows: i) The incidence of the
disease in Albanian children (25/100,000 in the age group
0–6 years) is much higher than in developed Mediterra-
nean countries endemic for VL; ii) The disease is associated
with poor sanitary conditions as suggested by the high
rate of severe clinical features and frequency of co-
morbidities; iii) The cheapest drug available for Mediter-
ranean VL treatment (meglumine antimoniate) is highly
effective (99% full cure rate) and well tolerated. Limitations
were identified in the low standard laboratory diagnostic
capability and unsatisfactory medical surveillance in less
urbanized areas. An improvement is warranted of a
disease-specific surveillance system in Albania.
Infantile Visceral Leishmaniasis, Albania
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manifestations in 5%; 3% of patients had salmonellosis.
VL diagnosis
In 938 patients (77.5%) the bone-marrow aspirate resulted
positive for the microscopic research of Leishmania amastigotes.
Cultures of bone marrow aspirates, performed in one fourth of the
patients, resulted positive in 65% of cases, all being positive also to
microscopy. Serology was performed in a limited number of bone-
marrow positive patients (40), providing however some informa-
tion on the validity of the commercial kits employed: 20 sera were
examined by IFAT and 20 by ELISA (a retrospective evaluation
included also 27 patients without leishmaniasis but affected by
other systemic pathologies). Among the 272 patients in whom
bone-marrow smears did not reveal amastigotes, 203 (admitted
from 1999) have been examined serologically: 145 by IFAT and
58 by ELISA. Overall serology detected 195 clear positives in this
subgroup, and 39/40 in the bone-marrow positive subgroup.
Because there were 3 false weak positives among non-leishmaniasis
patients, the mean sensitivity and specificity values of the
combined IFAT and ELISA tests were estimated to be 96% and
92%, respectively. Finally, there were 69 patients with negative
bone marrow that could not be examined serologically because
admitted before 1999. These patients, and the 8 bone-marrow
negative patients with negative/border-line serology (for a total of
77/1,210, 6.4%) have been diagnosed as affected by VL because
they showed persisting clinical and laboratory features strongly
suggestive of the disease, other diseases were excluded, and
presumptive treatment administered resulted in clinical cure.
Treatment
All the patients were treated with meglumine antimoniate. Two
children died in course of treatment (0.16%), one for sepsis the
other for acute renal impairment. There were no cases of primary
clinical unresponsiveness to the first-line therapy. By the end of
Figure 2. Schematic map of Albania showing the stratification
by district of cumulative VL cases diagnosed in children from
1996 through 2009.
doi:10.1371/journal.pntd.0000814.g002
Table 1. Symptoms and signs of patients and data from
physical examination.
Symptoms
and signs
1
Frequency
(%)
Physical
examination
1
Frequency
(%)
Fever 95.4 Splenomegaly 100
Malaise 84.9 Hepatomegaly 100
Anorexia 81.9 Abdomen enlargement 73.0
Pallor 81.9 Dry skin 28.1
Weight loss 66.8 Lymphadenopathy 11.0
Perspiration 49.2 Hemorrhagic symptoms
2 6.5
Dry cough 29.6 Edema 2.0
Diarrhea 26.6
Vomiting 19.1
1More than one symptom and sign or clinical findings at physical examination
could be present in the same patient.
2Ecchymosis, petechiae, epistaxis, or bleeding in the sites of injection.
doi:10.1371/journal.pntd.0000814.t001
Table 2. Hematological and biochemical features recorded in
patients at admittance.
Finding Frequency (%)
Anemia degree (g/dL hemoglobin)
I (12.8 to 9.6) 11.5
II (9.5 to 6.4) 48.4
III (6.3 to 3.2) 38.4
IV (,3.2) 1.5
Reticulocytes increase above the normal range (%)
0–15 45.1
16–30 35.4
.30 9.6
Neutropenia (,30% neutrophils) 49.0
Lymphocytosis 33.5
Lymphopenia 34.6
Thrombocytopenia (,1.5610
5 platelets/mm
3)
1.4-1610
5 29.6
1-0.5610
5 16.3
5-1610
4 1.4
,1610
4 0.7
Erythrocyte sedimentation rate (.20 mm/Hg) 95.7%
Hypergammaglobulinemia 100
Elevated globulins/albumin ratio (.1.21) 100
Hypoproteinemia (,6.5 g/dl) 13.4
Serum creatinine increase 4.8
Liver enzyme (ALT) increase 0
doi:10.1371/journal.pntd.0000814.t002
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found negative in all patients. Eight patients (0.67%) showed a
clinical relapse of VL, confirmed parasitologically, within 6–12
months from therapy and needed re-treatment with liposomal
amphotericin B, which successfully cured these patients as assessed
by 1-year post-therapy follow-up. In 39% of the children treated
with meglumine antimoniate at least one adverse event was
recorded (Table 3). Patients treated with liposomal amphotericin B
did not show adverse events.
Discussion
Globally, there are an estimated 500,000 new cases of VL and
more than 50,000 deaths from the disease each year, however both
figures are approximations as VL is frequently not recognized or
not reported [2,11]. Migration, lack of control measures and HIV
co-infection are the three main factors reported for driving the
increased incidence of VL [12]. Poverty and leishmaniasis are also
strictly associated. Poor housing conditions and diet, poverty-
related concurrent infections as well as proximity to infected dogs,
are all specific factors related to zoonotic VL [13]. As regards the
VL transmission potential, at least 3 proven L.infantum vectors are
present Albania, Phlebotomus neglectus being the most widespread
and showing the highest relative density among Phlebotomus species
[9]. Although no systematic canine surveys have been performed
throughout the country, a few studies suggest that canine infec-
tions are widespread, with seroprevalence (IFAT) rates of 16–17%
recorded in several districts including Tirana (Teita Myrseli,
Institute of Public Health, Tirana, personal communication).
Our experience shows that VL in the pediatric age occurs
frequently in Albania, with a high number of per-year admissions
relatively constant during the 15-year period of observation. VL is
also recorded in adults [9]: from 1998 to 2008, 126 cases
diagnosed in the age groups 15–.60 years have been notified to
the Control of Infectious Diseases Department, Institute of Public
Health, Tirana. Furthermore, HIV-Leishmania co-infections have
been diagnosed in 26 adult patients out of some 300 HIV/AIDS
cases recorded from 1993 to 2010. These figures indicate that VL
is still largely an infantile disease in Albania, the children
representing 87.7% of total VL cases.
Being the surveillance system in Albania still in development we
can infer that the number of actual cases including the
undiagnosed or misdiagnosed ones could be even higher. In fact,
a high proportion of patients came from urbanized areas, therefore
small villages or farming areas might suffer from the phenomenon
of under-diagnosis in rural territories with a lower degree of
medical surveillance. According to the 2001 census, in Albania live
about 330.000 children under 6 years (www.instat.gov.al). Based
on our VL figures (90% of cases belong to this age group) we can
estimate an yearly incidence of 25/100.000 of this at-risk
population, which is much higher than commonly observed in
southern European countries endemic for VL [2,14].
Clinical presentation and laboratory findings reflect classic
features of a poverty-related disease. The relatively high number of
co-morbidities among the patients is noteworthy, as it is the
elevated prevalence of severe anemia; they may suggest poor
hygiene and diet deficiency, respectively. As regards the high
frequency of bronchopneumonia (84%), the Balkan continental
climate which dominates the weather in Albania (hot summer and
very cold winter in the inland territories) may have a role in
respiratory trait pathologies in debilitated children under poor
housing conditions.
Sensitivity of bone marrow microscopy for Leishmania diagnosis
(77.5%) was considerably lower than figures reported in published
cases series of Mediterranean VL, both in children (97.6%) and
adults (97.0%) [15,16]. This may reflect a low degree of accuracy
in performing the parasitological investigation. Starting from 1999
we could rely on commercial serological assays widely used in
European hospital laboratories. Through serology, we could
confirm the disease in 195/203 (96%) bone-marrow negative
patients with strong clinical evidence of VL and in whom other
systemic pathologies had been excluded. Only 6.4% of our
patients received presumptive treatment due to the lack of specific
VL diagnosis; all of them were clinically cured following penta-
valent antimony therapy. As regards the possibility that Leishmania
asymptomatic infections detected by serology were present in
children exhibiting VL-mimicking conditions, it should be pointed
out that differently from DAT or Western blot serological assays,
or PCR methods, IFAT and ELISA commercial kits hardly detect
L.infantum infections in children without overt clinical VL, and
when they do so antibody titers are around the cut-off [17,18].
Indeed, consultation with pediatric reference centres in developed
Mediterranean countries disclosed the general consensus that
presence of clinical signs and symptoms compatible with VL
associated with the detection of serum Leishmania antibodies are
established criteria for VL diagnosis alternative to Leishmania
demonstration in bone-marrow aspirates [19].
Discovered 60 years ago, pentavalent antimonials remain the
mainstay treatment of VL despite the long duration of administra-
tion and severe side effects which may be observed in some patients,
especially adults with underlying conditions [20]. Meglumine
antimoniate is still effective with more than 95% cure rate in those
Mediterranean countries where the drug is of routine use for VL
[21], whereas Leishmania antimony resistance is increasing in regions
where massive treatments of infected dogs with antimonials, such as
Italy and southern France, are common [22]. Anti-leishmanial
therapy of infected pets is not a usual practice in Albania, which
may explain the very high therapeutic efficacy of pentavalent
antimony exhibited in our patients (99.3% cure rate). Furthermore,
it appears that the drug was well tolerated in children. There were
no cases of primary unresponsiveness and the relapse rate was low
(0.7%). The few relapsing cases were treated successfully with a 7-
day course of liposomal amphotericin B without adverse events.
Treatment costs associated with this drug are not affordable by the
Albanianhealth system,therefore wehadtorelyonthecontribution
and assistance of foreign institutions (University of Bari, Italy).
Inconclusion,ourstudydiscloseda patternofpediatricVLwhich
is somehow different from that of neighboring developed Mediter-
ranean countries, despite sharing common Leishmania agents,
reservoir and vectors: incidence of clinical disease in childhood
and frequency of co-morbidities are by far more elevated, thus
reinforcing the concept that poverty and leishmaniasis are strictly
Table 3. Incidence of adverse events recorded in 1,210
pediatric patients treated with meglumine antimoniate.
Parameter Frequency (%)
Decrease of hemoglobin 20
Hyperamylasemia 10
Hypokalemia 7
ECG modifications 6
Hyponatremia 2
Nefrotoxicity 2
Liver enzyme (ALT) increase 1
doi:10.1371/journal.pntd.0000814.t003
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important limitations, first of all a low standard laboratory
diagnostic capability (as revealed by the scarce sensitivity of bone
marrow microscopy and unsatisfactory border-line serological
findings) associated to an over-emphasized use of presumptive
treatments and ex juvantibus diagnosis based on clinical experience.
Furthermore, the studied population may represent a biased sample
of patients living in urbanized areas where the passive medical
surveillance is more efficient. Therefore an improvement is
warranted of a disease-specific surveillance system in Albania which
includes training of laboratory staff in peripheral hospitals, active
search of the infection in febrile children resistant to antibiotic
therapies and the use of specific and sensitive methods for diagnosis
and follow-up.
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